Other diseases
Myasthenia gravis
重症肌无力
A disorder of the signal between nerves and muscles, with muscle weakness that worsens with use and antibodies to the acetylcholine receptor or MuSK. It may affect only the eye muscles, or also the face, swallowing, breathing and limbs. A tumour of the thymus (thymoma) is found in a minority of cases.
Definition adapted from MeSH (US National Library of Medicine), Mao 2012
Listed in China's first national rare-disease catalogue (2018, no. 32). The catalogue lists the narrower entry “generalised myasthenia gravis”. National Health Commission 国卫医发〔2018〕10号
- hospitals in mainland China
- 89
- cities
- 39
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 23% of the world's English-language research papers on myasthenia gravis, 2021–2025 (15% in 2016–2020), and 26% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
89 hospitals in 39 cities
Order: papers led on myasthenia gravis, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 2 papers or 1 trial on myasthenia gravis, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens myasthenia gravis in that city. 29 more cities are in the menu below.
- 31 papers led
- 28 papers ledNo open trial led
- 21 papers led
- 20 papers led
- 20 papers ledNo open trial led
- 17 papers led
- 16 papers ledNo open trial led
- 16 papers led
- 13 papers led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 39
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 33 papers led3 hospitals
- 29 papers led4 hospitals
- 28 papers led1 hospital
- 26 papers led6 hospitals
- 22 papers led3 hospitals
- 22 papers led2 hospitals
- 17 papers led1 hospital
- 17 papers led5 hospitals
- 17 papers led2 hospitals
- 14 papers led4 hospitals
- 13 papers led2 hospitals
- 13 papers led2 hospitals
- 12 papers led3 hospitals
- 12 papers led1 hospital
- 11 papers led3 hospitals
- 9 papers led1 hospital
- 8 papers led3 hospitals
- 7 papers led3 hospitals
- 7 papers led4 hospitals
- 6 papers led3 hospitals
- 6 papers led2 hospitals
- 6 papers led1 hospital
- 6 papers led4 hospitals
- 5 papers led2 hospitals
- 5 papers led1 hospital
- 5 papers led2 hospitals
- 4 papers led1 hospital
- 4 papers led1 hospital
- 3 papers led2 hospitals
- 3 papers led1 hospital
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 1 paper led2 hospitals
- 1 paper led1 hospital
- 1 paper led1 hospital
open trials on myasthenia gravis in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 29 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingA Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07249632
Age 12 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEfficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07413835
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- RecruitingClinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07470151
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07526493
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07622342
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Shanghai
- RecruitingA Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2025-03
- Registry
- NCT06688435
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan
- RecruitingUniversal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
- Phase
- Early phase 1
- Started
- 2025-06
- Registry
- NCT06939166
Age 18 years to Not stated (registered criteria)
Led by Tianjin Huanhu HospitalTianjin
- RecruitingSafety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Registry
- NCT07022197
Age 18 years to 60 years (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingGC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07058298
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingClinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07215650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou
- RecruitingCD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07337785
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingPrecision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT04535843
Age 0 years to 90 years (registered criteria)
Led by Huashan Hospital; 1 listed hospital as study siteShanghai
- RecruitingMyasthenia Gravis Registry in China
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06241521
Age not stated (registered criteria)
Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou
- RecruitingA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06249438
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingSafety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06371040
Age 18 years to 80 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingA Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06447597
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an, Zunyi
- RecruitingEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06463587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi
- RecruitingBiomarkers in Autoimmune Disease of Nervous System
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06502015
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingCohort Study on Neuroimmune Diseases in the Reproductive Age
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT07653984
Age 20 years to 55 years; women only (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingConstruction of A Multimodal Digital Assessment Model for Myasthenia Gravis
- Phase
- Not given
- Started
- 2023-08
- Registry
- NCT07146425
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingEfficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT05067348
Age 18 years to 80 years (registered criteria)
Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an
- RecruitingA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Phase
- Phase 3
- Started
- 2021-07
- Registry
- NCT04951622
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an
- RecruitingSafety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
- Phase
- Early phase 1
- Started
- 2020-09
- Registry
- NCT04561557
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingTheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
- Phase
- Not given
- Started
- 2019-11
- Registry
- NCT04182984
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- Not yet recruitingA Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07298928
Age Not stated to 18 years (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- Not yet recruitingTongji NADs Cohort
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07333196
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingUniversal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune Diseases
- Phase
- Early phase 1
- Started
- 2026-03
- Registry
- NCT07392528
Age 18 years to Not stated (registered criteria)
Led by Tianjin Huanhu HospitalTianjin
- Not yet recruitingEfficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
- Phase
- Phase 1
- Started
- 2026-12
- Registry
- NCT07556120
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- Not yet recruitingA Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07593911
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- Not yet recruitingA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07676266
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- Not yet recruitingUniversal STAR-T Cell Injection in Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07714798
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingAn Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07818291
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- Not yet recruitingA Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- Phase
- Early phase 1
- Started
- 2026-12
- Registry
- NCT07917923
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingUniversal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
- Phase
- Early phase 1
- Started
- 2025-02
- Registry
- NCT06485232
Age 18 years to 75 years (registered criteria)
Led by Xuanwu HospitalBeijing
- Not yet recruitingAn Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06759948
Age 18 years to 75 years (registered criteria)
Led by Huashan HospitalShanghai
- Not yet recruitingUCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
- Phase
- Early phase 1
- Started
- 2025-04
- Registry
- NCT06933563
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingUCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT06978738
Age 18 years to Not stated (registered criteria)
Led by Changzhou No.2 People's HospitalChangzhou
- Not yet recruitingEFG vs IVIG in TAMG
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07231523
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Rare disease diagnosis and treatment guideline (2019 edition), written for the first national rare-disease catalogueNational Health Commission 国卫办医函〔2019〕198号, 2019-02-27
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.